News

Natasha Hoyte, MPH, CPNP-PC, explains how important PrEP and PEP in school health programs can be for youth, and the crucial role awareness plays.

Lauren Flagg, DNP, APRN, CPNP-AC, discusses severe refractory status asthmaticus based on a session presented at the NAPNAP National Conference.

Of the 600,238 bivalent vaccine doses administered by all providers in the study period, 35,114 (5.9%) were done so by FRPP partners.

HCPs can provide resources to help parents make an informed decision.

Latest guidelines, treatments, and when to refer to a specialist.

The pediatric approval to treat CABP is 1 of 3 indications approved by the FDA.

The single-arm study has an estimated enrollment of 93 participants, made up of females aged 2 to 8 years and males aged 2 to 9 years with CPP.

The phase 3 portion of the AMPLITUDE trial will include adolescents aged 10 to 17 years.

The planned phase 1/2 INSPIRE Duchenne trial (NCT06138639) is a first in-human, open-label, multicenter trial to evaluate tolerability and safety of SGT-003.

New data demonstrates protection against new variants.

A discussion of human trafficking awareness and what primary care providers can do to spot red flags and implement evidence-based knowledge.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the April 2024 issue of Contemporary Pediatrics.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

NeuroStar Advanced Therapy becomes the first and only transcranial magnetic stimulation therapy cleared by the FDA as an adjunct treatment for patients 15 years and up with depression.

If approved, govorestat would be the first medication indicated for the treatment of galactosemia, a rare genetic metabolic disease resulting in an inability to metabolize simple sugar galactose.

Tenofovir alafenamide was approved in 2022 to treat pediatric patients aged 12 years and older.

IXINITY is now approved to treat all patients with the hemophilia B to help control bleeding episodes, as well as reduce the frequency of them.

Insights between the pandemics, with a highlight on the dose-response relationship, "could be valuable in preparing health care systems for future pandemics," concluded the investigators.

Sally Humphrey, DNP, APRN, CPNP-PC, discusses current technology to treat youth with diabetes. Humphrey highlights continuous glucose monitoring systems (CGMs) and how they have evolved and improved.

Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, provided a review and reminder of the CDC immunization recommendations and schedule during her session at the 45th National Association of Pediatric Nurse Practitioners (NAPNAP) National Conference on Pediatric Health Care in Denver, Colorado.

Psoriatic arthritis and spondyloarthritis occurred earlier in children and adolescents with IBD than in the matched references without IBD.

Ashley Gyura, DNP, CPNP-PC, provides updates presented at the 2024 NAPNAP National Conference, highlighting antiviral therapeutics for influenza, COVID-19, and herpes, among others.

The FTD will allow the development and review timeline of nipocalimab to accelerate. It is granted to drugs with the potential to treat severe conditions and provide unmet vital medical needs.

Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, shares her thoughts on the latest issue of Contemporary Pediatrics.

TNX-2900 was previously granted Orphan Drug designation by the federal agency in 2022 for the treatment of PWS.

The initial dose of pemivibart is 4500 mg, which is administered as a single intravenous infusion. A repeat 4500 mg dose should be administered every 3 months if ongoing protection is needed, stated the FDA.

As of March 21, 2024, 64 measles cases have been reported to the CDC by 17 jurisdictions.

The investigators concluded that age-related risk differences "highlight the necessity for tailored strategies, improving understanding of and treatment development for RVIs."